Zealand Pharma A/S, headquartered in Glostrup, Denmark, specializes in the development of innovative peptide formulations. The company focuses on a range of core technologies, including GLP-1 analogues, glucagon analogues, and amylin analogues, which are pivotal in addressing metabolic disorders. Zealand Pharma also explores cyclic peptides, dual agonists, and peptide conjugates, enhancing drug delivery systems and integrin inhibition. Their commitment to advancing peptide therapeutics positions them as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

94 Patents

#2 in Glostrup

#45 in Denmark

#8,204 in the World

Glostrup, Denmark

Zealand Pharma A/s

Forward Citations = 1,070

118 inventors:

Bjarne Due Larsen (35 out of 40 patents)

Ditte Riber (29 out of 32 patents)

Jakob Lind Tolborg (18 out of 19 patents)

4. Dieter Wolfgang Hamprecht (16 out of 36 patents)

5. Lise Giehm (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zealand Pharma A/s. Retrieved from https://idiyas.com/company/zealand-pharma-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

20 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

55 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]